nach oben

Current Diabetes Reports

Erschienen in:

01.04.2014 | Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Sulfonylureas: A New Look at Old Therapy

verfasst von: Peter M. Thulé, Guillermo Umpierrez

Erschienen in: Current Diabetes Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Sulfonylurea compounds were the first available oral antidiabetic agents and they remain an important tool in our quest for optimal glucose control. The sulfonylureas stimulate the release of insulin from pancreatic β-cells and have a number of extrapancreatic effects, including decreasing hepatic insulin clearance and reducing glucagon secretion in patients with type 2 diabetes. Although these agents have been the mainstay of pharmacotherapy for patients with type 2 diabetes mellitus (T2DM), their safety and clinical utility has been a matter of active debate in recent years, as their use is associated with risks of hypoglycemia and weight gain. We review the discovery and mechanisms of action of sulfonylureas, and the results of clinical trials to provide practical information on the pros and cons of their use in clinical practice. This review addresses advances in our understanding of mechanisms of action of sulfonylurea agents, their efficacy in T2DM, side effects, and impact on cardiovascular disease outcomes.

Campbell I. Sulfonylureas and hypoglycemia. Diabet Hypoglycemia. 2009;2:3–10.

Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981;22:295–320.PubMedCrossRef

Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. Drugs. 1981;22:211–45.PubMedCrossRef

Janbon MCJ, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montpellier Med. 1942;441:21–2.

Loubatieres A, Mariani MM, Chapal J. [Insulin secretion as studied on isolated perfused rat pancreas. I. Synergism between glucose and hypoglycaemic sulphonamides]. Diabetologia. 1970;6:457–66.PubMedCrossRef

Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231–45.PubMedCrossRef

Seltzer HS. Efficacy and safety of oral hypoglycemic agents. Annu Rev Med. 1980;31:261–72.PubMedCrossRef

Tommasini R. Pharmacological activity of glipizide. Curr Med Res Opin. 1975;3 Suppl 1:7–19.CrossRef

Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther. 2003;25:799–816.PubMedCrossRef

10.

Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS) [corrected]. Vasc Health Risk Manag. 2012;8:463–72.PubMedCentralPubMedCrossRef

11.

Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin N Am. 2001;30:909–33.CrossRef

12.••

Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011;60:1–23. Up-to-date review of pharmacological agents available for the management of patients with diabetes type 2.PubMedCentralPubMedCrossRef

13.

Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metabol. 2012;14 Suppl 1:9–13.CrossRef

14.

Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res. 2008;102:164–76.PubMedCrossRef

15.

Seino S, Zhang C, Shibasaki T. Sulfonylurea action re-visited. J Diabetes Invest. 2010;1:37–9.CrossRef

16.

Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115:2047–58.PubMedCentralPubMedCrossRef

17.

Herbst KJ, Coltharp C, Amzel LM, Zhang J. Direct activation of Epac by sulfonylurea is isoform selective. Chem Biol. 2011;18:243–51.PubMedCentralPubMedCrossRef

18.

Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325:607–10.PubMedCrossRef

19.

Rehmann H. Epac2: a sulfonylurea receptor? Biochem Soc Trans. 2012;40:6–10.PubMedCrossRef

20.

Marshall A, Gingerich RL, Wright PH. Hepatic effect of sulfonylureas. Metabolism. 1970;19:1046–52.PubMedCrossRef

21.

Simpson HC, Sturley R, Stirling CA, Reckless JP. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients. Diabet Med. 1990;7:143–7.PubMedCrossRef

22.

Groop L, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care. 1987;10:671–8.PubMedCrossRef

23.

Scheen AJ, Lefebvre PJ, Luyckx AS. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients. Eur J Clin Pharmacol. 1984;26:471–4.PubMedCrossRef

24.

Scheen AJ, Castillo MJ, Lefebvre PJ. Decreased or increased insulin metabolism after glipizide in type II diabetes. Diabetes Care. 1988;11:687–9.PubMed

25.

Barzilai N, Groop PH, Groop L, DeFronzo RA. A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. Acta Diabetol. 1995;32:273–8.PubMedCrossRef

26.

Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84:3140–5.PubMed

27.

ter Braak EW, Appelman AM, van der Tweel I, Erkelens DW, van Haeften TW. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care. 2002;25:107–12.PubMedCrossRef

28.

Bohannon NV, Lorenzi M, Grodsky GM, Karam JH. Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1982;54:459–62.PubMedCrossRef

29.

Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153:1039–48.PubMedCentralPubMedCrossRef

30.

Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610–30.PubMedCrossRef

31.

Mandarino LJ, Gerich JE. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in noninsulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care. 1984;7 Suppl 1:89–99.PubMed

32.

Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med. 2000;6:907–33.PubMedCentralPubMed

33.

Tracewell WG, Stalker DJ, Maloley PA, Gallagher TF, Gwilt PR. Population pharmacokinetics of glyburide in patients with well-controlled diabetes. Pharmacotherapy. 1998;18:51–6.PubMed

34.

Overkamp D, Volk A, Maerker E, et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002;25:2065–73.PubMedCrossRef

35.

Pernet A, Trimble ER, Kuntschen F, Assal JP, Hahn C, Renold AE. Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab. 1985;61:247–51.PubMedCrossRef

36.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCentralPubMedCrossRef

37.

International Diabetes Federation Clinical Guidelines Task Force. Global guidelines for type 2 diabetes. 2005. Available from: http://www.idf.org/Global_guideline. Accessed March 29.

38.

Group U. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef

39.

Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43.PubMedCrossRef

40.

Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS. Diabetic ketoacidosis in obese African-Americans. Diabetes. 1995;44:790–5.PubMedCrossRef

41.

Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84–90.PubMedCentralPubMedCrossRef

42.

Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease–recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly. 2012;142:w13629.PubMed

43.

Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176–80.PubMedCrossRef

44.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef

45.

Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389–94.PubMedCrossRef

46.

Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8.PubMedCrossRef

47.

Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394–403.PubMedCrossRef

48.

Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.PubMedCrossRef

49.

Nyback-Nakell A, Bergstrom J, Adamson U, Lins PE, Landstedt-Hallin L. Decreasing postprandial C-peptide levels over time are not associated with long-term use of sulphonylurea: an observational study. Diabetes Metab. 2010;36:375–80.PubMedCrossRef

50.

Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501–6.PubMedCrossRef

51.

Shin MS, Yu JH, Jung CH, et al. The duration of sulfonylurea treatment is associated with beta-cell dysfunction in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2012;14:1033–42.PubMedCrossRef

52.

Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin vs sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003;26:2231–7.PubMedCrossRef

53.•

Harrison LB, Adams-Huet B, Raskin P, Lingvay I. Beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35:1406–12. Up-to-date review of pharmacological agents available for the management of patients with diabetes type 2.PubMedCentralPubMedCrossRef

54.••

Nichols CG, Remedi MS. The diabetic beta-cell: hyperstimulated vs hyperexcited. Diabetes Obes Metab. 2012;14 Suppl 3:129–35. Up-to-date review of pharmacological agents available for the management of patients with diabetes type 2.PubMedCentralPubMedCrossRef

55.

Remedi MS, Nichols CG. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med. 2008;5:e206.PubMedCentralPubMedCrossRef

56.

Remedi MS, Kurata HT, Scott A, et al. Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus. Cell Metabol. 2009;9:140–51.CrossRef

57.

Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789–830.PubMed

58.

The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes. 1975;24 Suppl 1:65–184.

59.

Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J. 2006;174:169–74.

60.

Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care. 2009;32 Suppl 2:S337–41.PubMedCentralPubMedCrossRef

61.

Vegh A, Papp JG. Haemodynamic and other effects of sulphonylurea drugs on the heart. Diabetes Res Clin Pract. 1996;31(Suppl):S43–53.PubMedCrossRef

62.

Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metab. 2012;14 Suppl 1:9–13.PubMedCrossRef

63.

Billman GE. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol Therapeut. 2008;120:54–70.CrossRef

64.

Lomuscio A, Fiorentini C. Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Diabetes Res Clin Pract. 1996;31(Suppl):S21–6.PubMedCrossRef

65.

Aronson D, Mittleman MA, Burger AJ. Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure. PACE Pacing Clin Electrophysiol. 2003;26:1254–61.PubMedCrossRef

66.

Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531–7.PubMedCrossRef

67.

Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism. 2006;55(5 Suppl 1):S16–9.PubMedCrossRef

68.

Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–28.PubMedCrossRef

69.

Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef

70.

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRef

71.

Nagendran J, Oudit GY, Bakal JA, Light PE, Dyck JR, McAlister FA. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes? Diabetes Obes Metab. 2013;15:1022–8.PubMedCrossRef

72.

Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004;27:201–7.PubMedCrossRef

73.

Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metabol. 2013;15:938–53.CrossRef

74.

Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes. 2004;53 Suppl 3:S156–64.PubMedCrossRef

75.

Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Anti-diabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prevent. 2013;22(12):2258–68.CrossRef

76.

Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:E1170–5.PubMedCrossRef

77.

Bo S, Castiglione A, Ghigo E, et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol. 2013;169:117–26.PubMedCrossRef

78.

Holman RR, Paul SK, Berthel A, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef

79.

TBDS Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.CrossRef

Titel: Sulfonylureas: A New Look at Old Therapy
verfasst von: Peter M. Thulé
Guillermo Umpierrez
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 4/2014
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-014-0473-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Systematic Reviews to Ascertain the Safety of Diabetes Medications

Does Disruption of Circadian Rhythms Contribute to Beta-Cell Failure in Type 2 Diabetes?

Behavioral Contributions to the Pathogenesis of Type 2 Diabetes

Rational Use of Electronic Health Records for Diabetes Population Management

Alzheimer’s Disease and Type 2 Diabetes: Multiple Mechanisms Contribute to Interactions